Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors

BACKGROUND: This study aims to explore the efficacy and safety of mirabegron in treating irritative symptoms induced by intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) after transurethral resection of bladder tumors (TURBT). METHODS: A total of 160 patients subjected to TURBT was rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kai, Wang, Di, Wu, Gang, Ma, Jian, Wang, Tianqi, Wu, Jitao, Wang, Jipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559481/
https://www.ncbi.nlm.nih.gov/pubmed/34547193
http://dx.doi.org/10.1002/cam4.4278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559481/
https://www.ncbi.nlm.nih.gov/pubmed/34547193
http://dx.doi.org/10.1002/cam4.4278

Ejemplares similares